NCT00379977View on ClinicalTrials.gov

Study to Assess the Safety & Reactogenicity of GSK Biologicals' DTPa/Hib Vaccine When Given at 3, 4 and 5 Months of Age

PHASE3CompletedINTERVENTIONAL

Enrollment

30

Participants

Timeline

Start Date

September 30, 2006

Study Completion Date

December 31, 2006

Conditions

TetanusHaemophilus Influenzae Type bAcellular PertussisDiphtheria

Interventions

BIOLOGICAL

diphtheria, tetanus, pertussis & Hib vaccine

Trial Locations (1)

530021

GSK Investigational Site, Nanning

Sponsors

Lead Sponsor

GlaxoSmithKline

All Listed Sponsors

lead

GlaxoSmithKline

INDUSTRY

NCT00379977 - Study to Assess the Safety & Reactogenicity of GSK Biologicals' DTPa/Hib Vaccine When Given at 3, 4 and 5 Months of Age | Biotech Hunter | Biotech Hunter